Pondicherry Journal of Nursing

Register      Login

VOLUME 15 , ISSUE 1 ( January-March, 2022 ) > List of Articles

View Point

Drug Profile: Ryaltris Nasal Spray

Panneerselvam Rajaveni, Poongodi Venkatesan

Keywords : Nasal spray, Ryaltris, Seasonal allergic rhinitis

Citation Information : Rajaveni P, Venkatesan P. Drug Profile: Ryaltris Nasal Spray. 2022; 15 (1):19-21.

DOI: 10.5005/jp-journals-10084-13135

License: CC BY-NC 4.0

Published Online: 13-06-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Ryaltris is a metered, fixed-dose, prescribing nasal spray that delivers 665 µg of olopatadine hydrochloride, an antihistamine, and 25 µg of mometasone furoate monohydrate, a corticosteroid, in each spray. Ryaltris (olopatadine hydrochloride, mometasone furoate monohydrate) nasal spray has been approved by the Food and Drug Administration (FDA) for patients with 12 years and above for the treatment of symptoms associated with seasonal allergic rhinitis seasonal allergic rhinitis (SAR).

  1. FDA Approves ryaltris (mometasone and olopatadine) nasal spray. Glenmark Pharmaceuticals Inc; 2022. Available from: https://www.drugs.com/newdrugs.html.
  2. Ryaltris nasal spray–NPS medicine. Available from: https://www.nps.org.au/medicine-finder/ryaltris-nasal-spray.
  3. Stewart J. Ryaltris nasal spray: uses, dosage, side effects & warnings. Drugs.com; 2022. Available from: https://www.drugs.com/ryaltris.html.
  4. Cunha JP. Ryaltris. Side Effects Drug Center; 2022. Available from: https://www.rxlist.com/ryaltris-drug.htm.
  5. Ryaltris 25 micrograms/actuation + 600 micrograms/actuation nasal spray suspension. Glenmark Pharmaceuticals Europe Ltd; 2021. Available from: https://www.medicines.org.uk/emc/product/12898/smpc.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.